康哲药业获得1类新药MG-K10人源化单抗注射液新增慢性阻塞性肺疾病适应症药物临床试验批准通知书

Core Viewpoint - Kangzheng Pharmaceutical (00867) has received approval from the National Medical Products Administration (NMPA) for clinical trials of its new drug MG-K10, a humanized monoclonal antibody targeting IL-4Rα, for chronic obstructive pulmonary disease (COPD) [1] Group 1 - The drug MG-K10 has been granted a clinical trial approval notice by NMPA, allowing the company to proceed with trials for COPD [1] - The company holds co-development rights (excluding atopic dermatitis) and exclusive commercialization rights for MG-K10 [1]